Global Vasomotor Symptoms Market

Vasomotor Symptoms Market Size, Share, Growth Analysis, By Therapy type(Hormonal, and Non-Hormonal), By Distribution Channel(Hospital pharmacies, Retail pharmacies) - Industry Forecast 2024-2031

Report ID: SQMIG35A2784 | Region: Global | Published Date: April, 2024
Pages: 219 | Tables: 62 | Figures: 69

Vasomotor Symptoms Market News

  • In 2020, Novo Nordisk made an important announcement regarding FDA approval of its new non-hormone drug Rybelsus. Rybelsus was originally developed to treat type 2 diabetes, and has shown additional benefits in women by reducing the frequency and severity of hot flashes. These two effects demonstrate the reversible potential of existing medications that have been used to eliminate the neurological symptoms in addition to the primary symptoms.
  • In 2021, Evgen Pharma received FDA approval to begin Phase II clinical trials for its non-hormonal drug, SFX-01. This trial focuses on evaluating the effectiveness of SFX-01 in reducing hot flashes and night sweats in women with breast cancer. These developments point to a promising trend in medicine, which includes the discovery and repurposing of non-hormonal agents to relieve neuromuscular symptoms, thus providing individuals facing these complications have received effective treatments.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Vasomotor Symptoms Market size was valued at USD 3.5 billion in 2022 and is poised to grow from USD 3.74 billion in 2023 to USD 6.38 billion by 2031, growing at a CAGR of 6.90% in the forecast period (2024-2031).

The competitive environment of the Vasomotor Symptoms market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry. 'Bayer AG', 'Fervent Pharmaceuticals, LLC', 'Astellas Pharma Inc.', 'Frazier Healthcare Partners', 'Mitsubishi Tanabe Pharma Corporation', 'Eli Lilly and Company', 'AbbVie Inc.', 'AMAG Pharmaceuticals Inc.', 'Emcure Pharmaceuticals Limited', 'Merck & Co., Inc.', 'Novartis AG', 'Novo Nordisk A/S', 'Pfizer Inc.', 'Teva Pharmaceutical Industries Ltd.'

Research and development (R&D) programs and clinical trials play an important role in increasing our understanding of the underlying mechanisms of neurological symptoms, including mutations and physiology. This increased understanding could pave the way for more targeted and effective therapies, allowing researchers to work to develop new therapies by further exploring the complexity of neurological disorders through clinical trials contributing to the market’s high compound annual growth rate (CAGR). These trials not only expand the range of treatment options available, but also drive market growth by introducing innovative solutions.

The introduction of new interventions or the development of new treatments has the potential to increase awareness of vasomotor symptoms (VMS) and the importance of effective treatment This improved awareness can lead to actively seeking women symptom relief has increased, thus creating a larger market for VMS treatment Can Companies that specialize in introducing new products or new treatments for VMS stand to gain a competitive advantage in the market. This advantage is especially important if the drug is to establish itself as the treatment of choice for healthcare professionals and patients.

The North America vasomotor symptoms market is valued at US$ 1.6 billion by 2022 and is poised to exhibit a noteworthy growth rate at a compound annual growth rate (CAGR) during the analyzed period. This strong growth is primarily related to syndromes associated with vasomotor issues Besides being due to the readily available knowledge of the availability of relaxing drugs, common symptoms of inflammation widespread around the time of menopause gain market significant impact on development.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Surgical Retractor Market
Buy Now GET FREE SAMPLE
Non-Powered Air Purifying Respirator Market
Buy Now GET FREE SAMPLE
Medical Tricorder Market
Buy Now GET FREE SAMPLE
Powered Wheelchair Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Vasomotor Symptoms Market

Product ID: SQMIG35A2784

$5,300
BUY NOW GET FREE SAMPLE